Andrew Donson
Concepts (414)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ependymoma | 25 | 2023 | 155 | 5.390 |
Why?
| Brain Neoplasms | 40 | 2024 | 979 | 4.360 |
Why?
| Infratentorial Neoplasms | 6 | 2023 | 45 | 2.100 |
Why?
| Glioma | 15 | 2024 | 294 | 1.910 |
Why?
| Medulloblastoma | 15 | 2023 | 172 | 1.710 |
Why?
| Astrocytoma | 12 | 2023 | 108 | 1.650 |
Why?
| Gene Expression Regulation, Neoplastic | 24 | 2022 | 1143 | 1.610 |
Why?
| Glioblastoma | 14 | 2019 | 253 | 1.570 |
Why?
| Gene Expression Profiling | 26 | 2024 | 1518 | 1.410 |
Why?
| Brain Stem Neoplasms | 9 | 2023 | 86 | 1.390 |
Why?
| Craniopharyngioma | 6 | 2020 | 65 | 1.280 |
Why?
| Cerebellar Neoplasms | 9 | 2023 | 130 | 1.240 |
Why?
| Rhabdoid Tumor | 10 | 2022 | 80 | 1.010 |
Why?
| Central Nervous System Neoplasms | 9 | 2021 | 126 | 0.980 |
Why?
| Pituitary Neoplasms | 4 | 2020 | 157 | 0.950 |
Why?
| Ganglioglioma | 4 | 2017 | 31 | 0.810 |
Why?
| Biomarkers, Tumor | 11 | 2019 | 1040 | 0.810 |
Why?
| Proto-Oncogene Proteins B-raf | 5 | 2017 | 192 | 0.760 |
Why?
| Drug Screening Assays, Antitumor | 5 | 2021 | 181 | 0.750 |
Why?
| Transcriptome | 10 | 2023 | 726 | 0.710 |
Why?
| Neoplasm Recurrence, Local | 8 | 2021 | 859 | 0.700 |
Why?
| Cell Line, Tumor | 25 | 2022 | 2711 | 0.680 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 59 | 0.680 |
Why?
| Radiation Tolerance | 6 | 2022 | 92 | 0.670 |
Why?
| Single-Cell Analysis | 2 | 2021 | 189 | 0.660 |
Why?
| Child | 46 | 2024 | 18422 | 0.590 |
Why?
| Cyst Fluid | 1 | 2017 | 27 | 0.580 |
Why?
| Antineoplastic Agents | 7 | 2022 | 1879 | 0.570 |
Why?
| Oligonucleotide Array Sequence Analysis | 19 | 2016 | 740 | 0.520 |
Why?
| Radiation | 3 | 2021 | 24 | 0.520 |
Why?
| Teratoma | 6 | 2022 | 92 | 0.520 |
Why?
| Cell Cycle Proteins | 6 | 2022 | 551 | 0.500 |
Why?
| Humans | 97 | 2024 | 114709 | 0.500 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2020 | 67 | 0.480 |
Why?
| DNA Methylation | 7 | 2021 | 496 | 0.470 |
Why?
| Cancer Vaccines | 2 | 2010 | 137 | 0.460 |
Why?
| Child, Preschool | 29 | 2021 | 9119 | 0.450 |
Why?
| Tumor Microenvironment | 6 | 2023 | 430 | 0.440 |
Why?
| Cytokines | 4 | 2018 | 1841 | 0.390 |
Why?
| Radiation-Sensitizing Agents | 3 | 2016 | 38 | 0.390 |
Why?
| Cell Proliferation | 17 | 2022 | 2187 | 0.370 |
Why?
| Neoplasm Proteins | 3 | 2012 | 385 | 0.370 |
Why?
| Survivors | 2 | 2023 | 411 | 0.370 |
Why?
| Tumor Suppressor Proteins | 2 | 2017 | 282 | 0.360 |
Why?
| Prognosis | 15 | 2023 | 3330 | 0.360 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2021 | 17 | 0.350 |
Why?
| Chromosome Aberrations | 2 | 2023 | 135 | 0.350 |
Why?
| Histones | 4 | 2021 | 535 | 0.340 |
Why?
| Apoptosis | 14 | 2022 | 2363 | 0.340 |
Why?
| Supratentorial Neoplasms | 2 | 2021 | 17 | 0.330 |
Why?
| Protein-Tyrosine Kinases | 4 | 2019 | 395 | 0.330 |
Why?
| Proto-Oncogene Proteins | 5 | 2022 | 608 | 0.320 |
Why?
| Pyrimidines | 6 | 2017 | 376 | 0.320 |
Why?
| Drug Resistance, Neoplasm | 5 | 2017 | 638 | 0.320 |
Why?
| Oncogene Proteins, Fusion | 2 | 2021 | 179 | 0.320 |
Why?
| Microarray Analysis | 7 | 2017 | 118 | 0.320 |
Why?
| Quinazolines | 3 | 2022 | 240 | 0.310 |
Why?
| Nuclear Proteins | 4 | 2017 | 591 | 0.310 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 1356 | 0.310 |
Why?
| MAP Kinase Signaling System | 2 | 2021 | 276 | 0.300 |
Why?
| Mutation | 7 | 2021 | 3346 | 0.300 |
Why?
| DNA Modification Methylases | 1 | 2007 | 14 | 0.280 |
Why?
| Chemoradiotherapy | 2 | 2019 | 188 | 0.280 |
Why?
| DNA Repair Enzymes | 1 | 2007 | 22 | 0.280 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2007 | 68 | 0.280 |
Why?
| Infant | 17 | 2020 | 7964 | 0.280 |
Why?
| Dacarbazine | 1 | 2007 | 99 | 0.280 |
Why?
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 37 | 0.270 |
Why?
| B7-H1 Antigen | 2 | 2018 | 139 | 0.270 |
Why?
| RNA, Messenger | 8 | 2017 | 2553 | 0.260 |
Why?
| Immunohistochemistry | 6 | 2017 | 1629 | 0.260 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 850 | 0.260 |
Why?
| Adolescent | 23 | 2021 | 17855 | 0.260 |
Why?
| Chloroquine | 2 | 2017 | 52 | 0.250 |
Why?
| Cisplatin | 3 | 2016 | 262 | 0.240 |
Why?
| Kaplan-Meier Estimate | 5 | 2021 | 811 | 0.240 |
Why?
| NF-kappa B | 2 | 2020 | 641 | 0.240 |
Why?
| Immunophenotyping | 2 | 2017 | 274 | 0.240 |
Why?
| DNA, Neoplasm | 2 | 2020 | 157 | 0.240 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 347 | 0.230 |
Why?
| Male | 34 | 2021 | 55609 | 0.230 |
Why?
| Neoplasms, Radiation-Induced | 3 | 2010 | 67 | 0.230 |
Why?
| Neurofibroma, Plexiform | 1 | 2023 | 5 | 0.220 |
Why?
| Female | 34 | 2021 | 59523 | 0.220 |
Why?
| Pyrazoles | 5 | 2022 | 362 | 0.220 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 521 | 0.220 |
Why?
| Transcription Factors | 5 | 2023 | 1528 | 0.220 |
Why?
| Indoles | 2 | 2017 | 304 | 0.210 |
Why?
| Autophagy | 2 | 2017 | 235 | 0.210 |
Why?
| Neurofibromatosis 1 | 1 | 2023 | 36 | 0.210 |
Why?
| Chromosomes | 1 | 2023 | 85 | 0.210 |
Why?
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2021 | 40 | 0.210 |
Why?
| Survival Analysis | 3 | 2023 | 1211 | 0.210 |
Why?
| Tamoxifen | 2 | 2004 | 191 | 0.200 |
Why?
| Cell Survival | 8 | 2020 | 1021 | 0.200 |
Why?
| Sulfonamides | 2 | 2017 | 445 | 0.200 |
Why?
| raf Kinases | 1 | 2021 | 11 | 0.200 |
Why?
| Vaccination | 1 | 2010 | 1204 | 0.200 |
Why?
| Cohort Studies | 9 | 2021 | 4895 | 0.190 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 14 | 0.190 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 56 | 0.190 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2023 | 167 | 0.190 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 57 | 0.190 |
Why?
| Cell Cycle | 8 | 2017 | 542 | 0.190 |
Why?
| Receptor, ErbB-3 | 2 | 2015 | 41 | 0.190 |
Why?
| Gene Amplification | 1 | 2021 | 95 | 0.190 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.190 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2021 | 63 | 0.180 |
Why?
| Receptor, trkB | 1 | 2021 | 28 | 0.180 |
Why?
| Gene Expression | 4 | 2015 | 1421 | 0.180 |
Why?
| DNA-Binding Proteins | 3 | 2021 | 1314 | 0.180 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 59 | 0.180 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 111 | 0.170 |
Why?
| B7 Antigens | 1 | 2020 | 9 | 0.170 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2020 | 40 | 0.170 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2020 | 64 | 0.170 |
Why?
| Anilides | 2 | 2010 | 67 | 0.170 |
Why?
| MicroRNAs | 2 | 2020 | 600 | 0.170 |
Why?
| Cell Transformation, Neoplastic | 3 | 2019 | 308 | 0.170 |
Why?
| Infant, Newborn | 8 | 2020 | 5047 | 0.170 |
Why?
| Genome, Human | 3 | 2021 | 347 | 0.160 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 923 | 0.160 |
Why?
| Cell Lineage | 1 | 2021 | 309 | 0.160 |
Why?
| Mice | 11 | 2023 | 14872 | 0.160 |
Why?
| SMARCB1 Protein | 1 | 2019 | 17 | 0.160 |
Why?
| Pteridines | 2 | 2016 | 20 | 0.160 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 430 | 0.160 |
Why?
| Aging | 2 | 2020 | 1618 | 0.160 |
Why?
| Protein Kinase C | 1 | 2000 | 273 | 0.150 |
Why?
| Dose-Response Relationship, Drug | 6 | 2017 | 1842 | 0.150 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 445 | 0.150 |
Why?
| ErbB Receptors | 2 | 2015 | 554 | 0.150 |
Why?
| Stromal Cells | 1 | 2018 | 97 | 0.150 |
Why?
| Computer Simulation | 2 | 2021 | 873 | 0.150 |
Why?
| Adenoviridae | 1 | 1998 | 184 | 0.150 |
Why?
| Meningioma | 2 | 2009 | 77 | 0.150 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 117 | 0.150 |
Why?
| SOXE Transcription Factors | 2 | 2016 | 17 | 0.150 |
Why?
| Drug Approval | 1 | 2018 | 78 | 0.150 |
Why?
| Everolimus | 1 | 2017 | 61 | 0.140 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 34 | 0.140 |
Why?
| Transcription Factor RelA | 1 | 2018 | 82 | 0.140 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 44 | 0.140 |
Why?
| Genes, p16 | 1 | 2017 | 16 | 0.140 |
Why?
| Phenotype | 4 | 2024 | 2797 | 0.140 |
Why?
| Retrospective Studies | 11 | 2020 | 12556 | 0.140 |
Why?
| E2F Transcription Factors | 1 | 2017 | 55 | 0.140 |
Why?
| Morpholines | 1 | 2017 | 102 | 0.140 |
Why?
| Spinal Neoplasms | 1 | 2017 | 28 | 0.140 |
Why?
| Genetic Therapy | 1 | 1998 | 257 | 0.140 |
Why?
| Stem Cells | 1 | 2021 | 546 | 0.140 |
Why?
| Young Adult | 9 | 2021 | 10472 | 0.140 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.130 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2018 | 194 | 0.130 |
Why?
| Image Processing, Computer-Assisted | 1 | 2020 | 685 | 0.130 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2021 | 801 | 0.130 |
Why?
| Disease Models, Animal | 3 | 2021 | 3535 | 0.130 |
Why?
| Myeloid Cells | 2 | 2015 | 126 | 0.130 |
Why?
| Blotting, Western | 6 | 2013 | 1147 | 0.130 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 132 | 0.130 |
Why?
| Flow Cytometry | 3 | 2006 | 1083 | 0.130 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 398 | 0.130 |
Why?
| EGF Family of Proteins | 1 | 2015 | 15 | 0.120 |
Why?
| Neuroectodermal Tumors, Primitive | 2 | 2012 | 12 | 0.120 |
Why?
| Receptor, EphA2 | 1 | 2015 | 19 | 0.120 |
Why?
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.120 |
Why?
| Proteins | 1 | 2021 | 908 | 0.120 |
Why?
| Pilomatrixoma | 1 | 2015 | 2 | 0.120 |
Why?
| Adult | 16 | 2023 | 30554 | 0.120 |
Why?
| Radiation, Ionizing | 2 | 2012 | 72 | 0.120 |
Why?
| Follow-Up Studies | 6 | 2020 | 4411 | 0.120 |
Why?
| Genetic Variation | 1 | 2019 | 870 | 0.120 |
Why?
| Mutation, Missense | 1 | 2016 | 293 | 0.120 |
Why?
| Animals | 12 | 2023 | 31709 | 0.120 |
Why?
| Drug Delivery Systems | 2 | 2015 | 296 | 0.120 |
Why?
| src-Family Kinases | 1 | 2015 | 88 | 0.120 |
Why?
| Activin Receptors, Type I | 1 | 2014 | 9 | 0.120 |
Why?
| RNA-Binding Proteins | 2 | 2015 | 345 | 0.110 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 173 | 0.110 |
Why?
| Deoxyribose | 1 | 2013 | 5 | 0.110 |
Why?
| Glutamate-Cysteine Ligase | 1 | 2013 | 14 | 0.110 |
Why?
| Survival Rate | 4 | 2020 | 1644 | 0.110 |
Why?
| Exons | 1 | 2013 | 302 | 0.100 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 2286 | 0.100 |
Why?
| Karyotyping | 4 | 2010 | 102 | 0.100 |
Why?
| Karnofsky Performance Status | 1 | 2012 | 36 | 0.100 |
Why?
| Acetylcysteine | 1 | 2013 | 141 | 0.100 |
Why?
| Isocitrate Dehydrogenase | 1 | 2012 | 38 | 0.100 |
Why?
| Receptors, Opioid | 1 | 2012 | 19 | 0.100 |
Why?
| Pons | 1 | 2012 | 30 | 0.100 |
Why?
| Central Nervous System | 1 | 2014 | 235 | 0.100 |
Why?
| Combined Modality Therapy | 4 | 2019 | 1121 | 0.100 |
Why?
| Databases, Factual | 1 | 2016 | 1125 | 0.100 |
Why?
| Age Factors | 2 | 2017 | 2894 | 0.100 |
Why?
| Protein Precursors | 1 | 2012 | 119 | 0.100 |
Why?
| Risk Factors | 4 | 2020 | 8634 | 0.090 |
Why?
| Interleukin-6 | 1 | 2015 | 676 | 0.090 |
Why?
| RNA, Small Interfering | 2 | 2010 | 535 | 0.090 |
Why?
| Protein Kinase Inhibitors | 3 | 2014 | 785 | 0.090 |
Why?
| Magnetic Resonance Imaging | 2 | 2020 | 3053 | 0.090 |
Why?
| Drug Synergism | 3 | 2017 | 317 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 154 | 0.090 |
Why?
| Acetaminophen | 1 | 2013 | 241 | 0.090 |
Why?
| Epigenomics | 2 | 2021 | 101 | 0.090 |
Why?
| Cluster Analysis | 3 | 2021 | 455 | 0.090 |
Why?
| Neoplasm Grading | 2 | 2021 | 242 | 0.090 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2011 | 198 | 0.090 |
Why?
| T-Lymphocytes | 2 | 2018 | 1737 | 0.090 |
Why?
| Astrocytes | 1 | 2011 | 162 | 0.080 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 88 | 0.080 |
Why?
| Spinal Cord Neoplasms | 1 | 2009 | 37 | 0.080 |
Why?
| Peripheral Nervous System Neoplasms | 1 | 2009 | 20 | 0.080 |
Why?
| Proportional Hazards Models | 1 | 2012 | 1075 | 0.080 |
Why?
| Hemangioma | 1 | 2009 | 41 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2013 | 327 | 0.080 |
Why?
| Enzyme Inhibitors | 4 | 2012 | 750 | 0.080 |
Why?
| Gene Ontology | 2 | 2021 | 46 | 0.080 |
Why?
| Sarcoma, Ewing | 1 | 2009 | 64 | 0.080 |
Why?
| Glucose | 1 | 2013 | 897 | 0.080 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 226 | 0.070 |
Why?
| Herpesvirus 3, Human | 1 | 2011 | 378 | 0.070 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 154 | 0.070 |
Why?
| Herpes Zoster | 1 | 2011 | 331 | 0.070 |
Why?
| Phosphorylation | 3 | 2017 | 1569 | 0.070 |
Why?
| Nerve Sheath Neoplasms | 1 | 2007 | 7 | 0.070 |
Why?
| Mesenchymoma | 1 | 2007 | 7 | 0.070 |
Why?
| Meningeal Neoplasms | 1 | 2008 | 87 | 0.070 |
Why?
| Aurora Kinases | 3 | 2012 | 28 | 0.070 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2019 | 699 | 0.070 |
Why?
| Etoposide | 1 | 2007 | 148 | 0.070 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2012 | 314 | 0.070 |
Why?
| Thymidine | 1 | 2006 | 58 | 0.070 |
Why?
| Aurora Kinase A | 3 | 2012 | 51 | 0.070 |
Why?
| Gene Silencing | 1 | 2007 | 171 | 0.070 |
Why?
| High Mobility Group Proteins | 1 | 2006 | 49 | 0.070 |
Why?
| Chromatin | 2 | 2020 | 428 | 0.070 |
Why?
| Cell Differentiation | 3 | 2020 | 1701 | 0.070 |
Why?
| Dose-Response Relationship, Radiation | 2 | 2012 | 127 | 0.070 |
Why?
| Nerve Tissue Proteins | 1 | 2009 | 530 | 0.060 |
Why?
| Piperazines | 2 | 2022 | 309 | 0.060 |
Why?
| Azepines | 2 | 2019 | 75 | 0.060 |
Why?
| Computational Biology | 2 | 2020 | 530 | 0.060 |
Why?
| Coculture Techniques | 2 | 2011 | 201 | 0.060 |
Why?
| In Situ Hybridization, Fluorescence | 3 | 2012 | 309 | 0.060 |
Why?
| Fatal Outcome | 2 | 2021 | 284 | 0.060 |
Why?
| Signal Transduction | 2 | 2015 | 4516 | 0.060 |
Why?
| Quality of Life | 1 | 2015 | 2353 | 0.060 |
Why?
| Pyrimidinones | 2 | 2016 | 88 | 0.060 |
Why?
| Benzamides | 2 | 2017 | 169 | 0.060 |
Why?
| Cell Division | 2 | 2010 | 758 | 0.060 |
Why?
| X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 14 | 0.060 |
Why?
| Middle Aged | 7 | 2021 | 26738 | 0.060 |
Why?
| Intelligence Tests | 1 | 2023 | 58 | 0.060 |
Why?
| RNA, Small Nuclear | 1 | 2023 | 31 | 0.060 |
Why?
| Genomics | 2 | 2021 | 635 | 0.050 |
Why?
| Cranial Irradiation | 1 | 2023 | 66 | 0.050 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2023 | 35 | 0.050 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2004 | 138 | 0.050 |
Why?
| Membrane Proteins | 1 | 2009 | 1019 | 0.050 |
Why?
| RNA | 2 | 2023 | 809 | 0.050 |
Why?
| Caspases | 1 | 2004 | 245 | 0.050 |
Why?
| Up-Regulation | 2 | 2016 | 808 | 0.050 |
Why?
| Transcription, Genetic | 2 | 2021 | 1313 | 0.050 |
Why?
| Pancreatic Neoplasms | 1 | 2009 | 731 | 0.050 |
Why?
| Cytidine Deaminase | 1 | 2023 | 58 | 0.050 |
Why?
| Sequence Analysis, DNA | 2 | 2016 | 723 | 0.050 |
Why?
| Brain Stem | 1 | 2023 | 101 | 0.050 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 41 | 0.050 |
Why?
| Disease Progression | 2 | 2023 | 2381 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2006 | 1694 | 0.050 |
Why?
| Septum Pellucidum | 1 | 2021 | 5 | 0.050 |
Why?
| Cerebellum | 1 | 2023 | 200 | 0.050 |
Why?
| Ligands | 1 | 2023 | 562 | 0.050 |
Why?
| Neoplasm Staging | 2 | 2017 | 1167 | 0.050 |
Why?
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 12 | 0.050 |
Why?
| Histone Deacetylases | 1 | 2023 | 195 | 0.050 |
Why?
| Mesencephalon | 1 | 2021 | 57 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2021 | 95 | 0.050 |
Why?
| Drug Evaluation, Preclinical | 2 | 2013 | 161 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 48 | 0.050 |
Why?
| DNA Damage | 2 | 2016 | 351 | 0.050 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 48 | 0.050 |
Why?
| Gene Rearrangement | 1 | 2021 | 135 | 0.050 |
Why?
| Hedgehog Proteins | 1 | 2022 | 172 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2021 | 168 | 0.040 |
Why?
| Preoperative Period | 1 | 2020 | 103 | 0.040 |
Why?
| Vinblastine | 1 | 2020 | 63 | 0.040 |
Why?
| Cell Fusion | 1 | 2020 | 50 | 0.040 |
Why?
| Repressor Proteins | 1 | 2023 | 366 | 0.040 |
Why?
| Carboplatin | 1 | 2020 | 135 | 0.040 |
Why?
| Signal-To-Noise Ratio | 1 | 2020 | 56 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2023 | 927 | 0.040 |
Why?
| RNA, Neoplasm | 2 | 2009 | 80 | 0.040 |
Why?
| Treatment Outcome | 2 | 2017 | 9088 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 314 | 0.040 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 43 | 0.040 |
Why?
| Protein Isoforms | 1 | 2000 | 338 | 0.040 |
Why?
| Pyridines | 2 | 2012 | 425 | 0.040 |
Why?
| Lysine | 1 | 2020 | 242 | 0.040 |
Why?
| Cell Self Renewal | 1 | 2019 | 49 | 0.040 |
Why?
| Benchmarking | 1 | 2020 | 161 | 0.040 |
Why?
| Odontogenesis | 1 | 2018 | 10 | 0.040 |
Why?
| Laser Capture Microdissection | 1 | 2018 | 23 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 555 | 0.040 |
Why?
| In Vitro Techniques | 1 | 2020 | 1016 | 0.040 |
Why?
| Tissue Culture Techniques | 1 | 2018 | 66 | 0.040 |
Why?
| Treatment Failure | 1 | 1999 | 331 | 0.040 |
Why?
| Triazoles | 1 | 2019 | 131 | 0.040 |
Why?
| HEK293 Cells | 1 | 2020 | 591 | 0.040 |
Why?
| Down-Regulation | 1 | 2000 | 594 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 23 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 18 | 0.040 |
Why?
| Genetic Vectors | 1 | 1998 | 289 | 0.040 |
Why?
| Cellular Senescence | 1 | 2019 | 152 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 55 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 29 | 0.040 |
Why?
| Fluorescent Antibody Technique | 1 | 2018 | 397 | 0.040 |
Why?
| Interleukin-2 | 1 | 1998 | 413 | 0.040 |
Why?
| Immune System | 1 | 1998 | 172 | 0.040 |
Why?
| Pituitary Gland | 1 | 2018 | 148 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 96 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 630 | 0.040 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 79 | 0.030 |
Why?
| Neuroglia | 1 | 2018 | 150 | 0.030 |
Why?
| Ki-67 Antigen | 1 | 2017 | 103 | 0.030 |
Why?
| Cetuximab | 1 | 2017 | 90 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2012 | 1342 | 0.030 |
Why?
| Models, Theoretical | 1 | 2020 | 515 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 439 | 0.030 |
Why?
| Camptothecin | 1 | 2017 | 96 | 0.030 |
Why?
| Benzodiazepinones | 1 | 2016 | 14 | 0.030 |
Why?
| Immune Tolerance | 1 | 1998 | 323 | 0.030 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 23 | 0.030 |
Why?
| Genes, myc | 1 | 2016 | 46 | 0.030 |
Why?
| Antigens, CD | 1 | 1998 | 442 | 0.030 |
Why?
| Urea | 1 | 2016 | 67 | 0.030 |
Why?
| Microscopy, Confocal | 1 | 2017 | 304 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2021 | 1950 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1998 | 339 | 0.030 |
Why?
| Amino Acid Substitution | 1 | 2016 | 262 | 0.030 |
Why?
| Aged | 4 | 2016 | 19074 | 0.030 |
Why?
| Thiophenes | 1 | 2016 | 108 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2018 | 386 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 337 | 0.030 |
Why?
| Mitosis | 1 | 2016 | 164 | 0.030 |
Why?
| Recombinant Proteins | 1 | 1998 | 1230 | 0.030 |
Why?
| Amphiregulin | 1 | 2015 | 21 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 343 | 0.030 |
Why?
| Gene Fusion | 1 | 2015 | 18 | 0.030 |
Why?
| HeLa Cells | 1 | 2016 | 562 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 620 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 81 | 0.030 |
Why?
| Gene Dosage | 1 | 2015 | 129 | 0.030 |
Why?
| Inhibitor of Differentiation Protein 2 | 1 | 2014 | 4 | 0.030 |
Why?
| Inhibitor of Differentiation Protein 1 | 1 | 2014 | 6 | 0.030 |
Why?
| Smad Proteins | 1 | 2014 | 39 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 512 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 55 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 1470 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 67 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2017 | 1131 | 0.030 |
Why?
| Phosphoproteins | 1 | 2015 | 298 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 134 | 0.030 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 318 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2020 | 2765 | 0.030 |
Why?
| HLA-DR Antigens | 1 | 2013 | 219 | 0.030 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 367 | 0.030 |
Why?
| Colorado | 1 | 2022 | 4100 | 0.030 |
Why?
| Catalysis | 1 | 2013 | 289 | 0.030 |
Why?
| Monocytes | 1 | 2015 | 504 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2015 | 477 | 0.020 |
Why?
| Glutathione | 1 | 2013 | 293 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 4694 | 0.020 |
Why?
| Tubulin | 1 | 2012 | 123 | 0.020 |
Why?
| Neural Stem Cells | 1 | 2012 | 115 | 0.020 |
Why?
| Acetylation | 1 | 2011 | 211 | 0.020 |
Why?
| RNA Interference | 1 | 2012 | 433 | 0.020 |
Why?
| Zebrafish | 1 | 2014 | 412 | 0.020 |
Why?
| c-Mer Tyrosine Kinase | 1 | 2010 | 43 | 0.020 |
Why?
| Choroid Plexus Neoplasms | 1 | 2009 | 8 | 0.020 |
Why?
| Papilloma | 1 | 2009 | 43 | 0.020 |
Why?
| Kinetics | 1 | 2013 | 1551 | 0.020 |
Why?
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 12 | 0.020 |
Why?
| Epilepsy | 1 | 2013 | 278 | 0.020 |
Why?
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 40 | 0.020 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2009 | 72 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2010 | 301 | 0.020 |
Why?
| Single-Blind Method | 1 | 2009 | 258 | 0.020 |
Why?
| Antibodies, Neoplasm | 1 | 2009 | 30 | 0.020 |
Why?
| Virus Replication | 1 | 2011 | 395 | 0.020 |
Why?
| Claudins | 1 | 2009 | 24 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2011 | 493 | 0.020 |
Why?
| Cytogenetics | 1 | 2008 | 11 | 0.020 |
Why?
| DNA Repair | 1 | 2009 | 184 | 0.020 |
Why?
| Inflammation | 1 | 2018 | 2480 | 0.020 |
Why?
| Paresis | 1 | 2007 | 28 | 0.020 |
Why?
| Biopsy | 1 | 2010 | 1036 | 0.020 |
Why?
| Hypothalamic Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
| Craniotomy | 1 | 2007 | 68 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2007 | 410 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 1880 | 0.020 |
Why?
| Multigene Family | 1 | 2007 | 190 | 0.020 |
Why?
| Vision Disorders | 1 | 2007 | 130 | 0.020 |
Why?
| Genetic Linkage | 1 | 2006 | 294 | 0.020 |
Why?
| Genetic Markers | 1 | 2006 | 320 | 0.020 |
Why?
| Neural Crest | 1 | 2006 | 117 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2007 | 321 | 0.020 |
Why?
| Caspase 3 | 1 | 2004 | 235 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 6347 | 0.010 |
Why?
| Brain | 1 | 2013 | 2371 | 0.010 |
Why?
| Enzyme Activation | 1 | 2004 | 785 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2006 | 2087 | 0.010 |
Why?
| Time Factors | 1 | 2008 | 6116 | 0.010 |
Why?
| Neoplasms | 1 | 2008 | 2097 | 0.010 |
Why?
|
|
Donson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|